endogenous retrovirus group K member 28Genealiases: []
Q-omics provides the consensus-scored ERVK-28 profile across patient tissues and cancer cell-line models. ERVK-28 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ERVK-28 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, ERVK-28 RNA expression shows 6,623 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, LUAD, and STAD as cancer lineages where ERVK-28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVK-28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVK-28 survival associations across molecular data types. ERVK-28 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVK-28 RNA expression–survival associations across cancer types. High ERVK-28 expression shows unfavorable associations in MESO, KICH, SKCM and THCA, but favorable associations in UCS and OV. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ERVK-28 RNA expression.
This table summarizes ERVK-28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ERVK-28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVK-28 shows lower tumor expression in BRCA and KICH and higher tumor expression in LUAD, KIRC, LUSC and COAD. The LUAD box plot shows higher ERVK-28 RNA expression in tumor versus normal tissue (log2 FC = +0.173, t-test p < 0.001).
This table shows molecular features associated with ERVK-28 in patient tissues and cancer cell lines. In patient samples, ERVK-28 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
